Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, marking its largest acquisition to date. The deal includes a promising drug called povetacicept, which is designed to treat IgA nephropathy (IgAN), a kidney autoimmune disorder affecting 130,000 people in the U.S. The drug will enter Phase 3 clinical development later this year. This acquisition expands Vertex’s portfolio of protein-based medicines that harness the immune system, showcasing their commitment to developing innovative treatments for a range of diseases. The companies announced the acquisition on Wednesday, signaling a significant step forward in the field of biopharmaceuticals.
Source link
Vertex to buy Alpine Immune Sciences for $4.9 billion
